February 7, 2013
In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an upcoming FDA decision on this Sunday, Feb. 10, on whether to approve Celgene's (NASDAQ: CELG ) drug pomalidomide, which is used in the treatment of blood cancer multiple myeloma. While there is little doubt that the drug will be approved, Brenton highlights the bigger question at stake here: Considering the competition in this space -- including one of Celgene's own drugs, which may cannibalize sales -- just how big will this drug become?
Should you give Celgene the green light?
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. If you're interested in owning the stock, you need to know about the key opportunities and risks facing the company. The Fool's brand new premium report on Celgene takes you through everything you need to know. To claim your copy today, simply click here now.
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013
." I invite you to take a copy, free for a limited time. Just click here
to access the report and find out the name of this under-the-radar company.